Physician profile

Douglas Combs

Obstetrics & Gynecology · Decatur, IL

NPI 1447218268

$4,420.67

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$19.07

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Intuitive Surgical, INC. $3,928.02 2019
Galderma Laboratories, L.P. $175.35 2020
Abbvie INC. $124.65 2019-2021
Bayer Healthcare Pharmaceuticals INC. $62.15 2019-2020
Lupin INC. $26.67 2019-2020
Kci USA, INC. $20.72 2020
Organon LLC $19.07 2024
Olympus America INC. $18.89 2019
Hologic Sales and Service, LLC $18.10 2019
Roche Diagnostics Corporation $16.23 2019
Therapeuticsmd, INC. $10.82 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Douglas Combs

$4,420.67

in general payments reported 2019-2025

Years
2019-2024
Top company
Intuitive Surgical, INC.

https://glasscript.com/doctor/831021/douglas-combs

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.